Researchers & Healthcare Professionals

www.lls.org/researchershealthcareprofessionals

Emerging Immunotherapies for Hematologic Malignancies: Improving Patient Outcomes by Harnessing the Immune System

Satellite Symposium Preceding the 56th Annual ASH Meeting

Date: December 5, 2014
Time: 7:00 a.m. - 11:00 a.m. PST
Location: San Francisco, CA
Target Audience: This activity is primarily for researchers in hematology/oncology, and for hematologists and oncologists who diagnose and treat patients with hematologic malignancies; it is also intended for others with an interest in hematologic malignancies.

Register

Activity Purpose

This program is designed to provide the intended audience with the most current and accurate information about therapeutic advances in immunology for treating and improving outcomes for patients with hematologic malignancies.

Education Objectives

After completing this activity, the participant should be better able to:

  • Describe advances in current understanding of immunology as they pertain to the treatment of hematologic malignancies
  • Explain the current status and therapeutic potential of immunotherapies for several hematologic malignancies
  • Demonstrate the ability to identify patients with hematologic malignancies who are appropriate candidates for an immuno-oncology treatment approach and engage them in discussions regarding clinical trials
  • Describe key factors related to moving immunotherapies forward in a timely fashion
  • Discuss the current technological advances, as well as the evolving knowledge about tumor targets, contributing to clinical advances using antibody drug conjugates to treat hematologic malignancies (This objective is addressed by Dr. Sievers' presentation, which is non-CME)

Faculty

Owen A. O'Connor, MD, PhD
Professor of Medicine and Experimental Therapeutics
Director, Center for Lymphoid Malignancies
Columbia University Medical Center
New York Presbyterian Hospital
New York, NY

Alexander M. Lesokhin, MD
Assistant Attending Physician, Myeloma Service and Immunotherapeutics Core
Memorial Sloan Kettering Cancer Center
New York, NY

John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Chair of Medical Oncology
Barts Cancer Institute
Barts and the London School of Medicine and Dentistry, Queen Mary University of London
London, UK

Helen E. Heslop, MD, DSc (Hon)
Dan L. Duncan Chair
Interim Director
, Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX

Michel Sadelain, MD, PhD
Stephen and Barbara Friedman Chair
Director
, Center for Cell Engineering
Member, Immunology Program
Sloan Kettering Institute
Member, Departments of Medicine and Pediatrics
Memorial Sloan Kettering Cancer Center
New York, NY

Eric Sievers, MD
Senior Vice President, Clinical Development
Seattle Genetics, Inc.
Bothell, WA

John C. McKew, PhD
Acting Scientific Director, Division of Pre-Clinical Innovation
National Center for Advancing Translational Sciences, National Institutes of Health
Bethesda, MD

Sponsors and Supporters

This activity is jointly provided by The Leukemia & Lymphoma Society, RMEI, LLC and Postgraduate Institute for Medicine. Funding provided by The Leukemia & Lymphoma Society.

last updated on Monday, August 11, 2014
btn_sharethis